122 related articles for article (PubMed ID: 11475503)
1. Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated.
Prescrire Int; 2000 Dec; 9(50):190-1. PubMed ID: 11475503
[TBL] [Abstract][Full Text] [Related]
2. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene: new preparation. Not better than oestrogen.
Prescrire Int; 1999 Dec; 8(44):165-7. PubMed ID: 11503811
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
[TBL] [Abstract][Full Text] [Related]
5. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.
Qu Y; Wong M; Thiebaud D; Stock JL
Curr Med Res Opin; 2005 Dec; 21(12):1955-9. PubMed ID: 16368046
[TBL] [Abstract][Full Text] [Related]
6. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
7. [SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].
Inaba M
Clin Calcium; 2004 Oct; 14(10):27-31. PubMed ID: 15577128
[TBL] [Abstract][Full Text] [Related]
8. [SERM for early osteoporosis therapy. Risk for first spinal fracture reduced to half].
MMW Fortschr Med; 2003 May; 145(22):57. PubMed ID: 12866287
[No Abstract] [Full Text] [Related]
9. Does raloxifene reduce risk of vertebral fractures? Is this another, brighter way to treat osteoporosis?
Hathirat S; Evans MF
Can Fam Physician; 2001 Oct; 47():1982-4. PubMed ID: 11723592
[No Abstract] [Full Text] [Related]
10. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
11. Raloxifene and risk for stroke based on the framingham stroke risk score.
Barrett-Connor E; Cox DA; Song J; Mitlak B; Mosca L; Grady D
Am J Med; 2009 Aug; 122(8):754-61. PubMed ID: 19540454
[TBL] [Abstract][Full Text] [Related]
12. [Compression vertebral fracture in osteoporosis--prevention and treatment].
Vlak T
Reumatizam; 2004; 51(2):50-3. PubMed ID: 15554379
[TBL] [Abstract][Full Text] [Related]
13. The use of raloxifene in osteoporosis treatment.
D'Amelio P; Isaia GC
Expert Opin Pharmacother; 2013 May; 14(7):949-56. PubMed ID: 23521229
[TBL] [Abstract][Full Text] [Related]
14. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
15. Reduction of vertebral fracture risk with raloxifene.
Bashore R
J Fam Pract; 1999 Nov; 48(11):911-2. PubMed ID: 10907630
[No Abstract] [Full Text] [Related]
16. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
[TBL] [Abstract][Full Text] [Related]
17. Safety assessment of raloxifene over eight years in a clinical trial setting.
Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
[TBL] [Abstract][Full Text] [Related]
18. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
Higuchi T; Mizunuma H
Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
[TBL] [Abstract][Full Text] [Related]
19. [Effects of SERMs on bone health. Efficacy of SERM for incidence of fractures in osteoporotic patients with lifestyle-related diseases].
Sakai A; Nakamura T
Clin Calcium; 2010 Mar; 20(3):322-9. PubMed ID: 20190361
[TBL] [Abstract][Full Text] [Related]
20. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
